What does Corteva do and what are its main business segments?

What is Corteva's latest dividend and current dividend yield?

What is Corteva's gross profit margin?

What is the market's earnings forecast for Corteva next quarter?

What were the key takeaways from Corteva’s earnings call?

What were the key takeaways from Corteva's earnings call?

What factors drove the changes in Corteva's revenue and profit?

What is the revenue and EPS growth rate for Corteva year over year?

- **Strategic Win with Bayer**: $1 billion+ earnings upside from accelerated corn licensing (2027 vs. 2032) and new cotton market entry, resolving $100 million annual royalty payments.
- **2026 Growth Drivers**: 7% EBITDA growth to $4.1 billion, royalty neutrality, and $200 million productivity savings offsetting $80 million tariffs.
- **Gene Editing Momentum**: EU regulatory approval expected Q2, enabling gene-edited products. U.S. disease-resistant corn hybrid launch within 1-2 years.
- **Strong Cash Position**: $2.9 billion free cash flow in 2025, ~$2.5 billion in 2026 (excluding separation costs), supporting dividend and buyback plans.
- **Market Leadership**: Seed order books strong, Crop Protection biologicals up double digits, and 2/3 portfolio differentiated to resist generic competition.

**【CEO Summary Section】**
- **Separation Update**: Corteva remains on track for a second-half 2026 separation, with SpinCo name and brand identity expected in Q2. CEO search for SpinCo is progressing, and IT system separation is planned for Q4.
- **Bayer Resolution**: $610 million paid to Bayer resolves all litigation, enabling Corteva to accelerate corn licensing (2027 vs. 2032) and enter cotton licensing. Expected $1 billion earnings upside over 10 years.
- **2025 Financial Highlights**: Operating EBITDA of $3.85 billion (+14% YoY), 22% margin, and $2.9 billion free cash flow. Seed business delivered $340 million net cost improvements, while Crop Protection saw $300 million productivity gains.
- **2026 Guidance**: Operating EBITDA $4.1 billion (+7%), driven by royalty neutrality, new product demand, and $200 million productivity. Free cash flow impacted by separation costs but still strong.

**【CFO Financial Commentary】**
- **Q4 2025 Results**: Sales $4.1 billion (-4% YoY), EBITDA $1.1 billion (-12% YoY) due to volume declines and higher costs. Full-year EBITDA $3.85 billion (+14%), margin 22.2%.
- **2026 Outlook**: EBITDA $4.1 billion (+7%), EPS $3.57-3.70, free cash flow ~$2.5 billion (excluding separation costs). Royalty expense to neutralize in 2026, 2 years ahead of prior plan.
- **Key Drivers**: Seed licensing growth (Conkesta soybeans, Enlist corn), Crop Protection new product adoption, and $200 million productivity savings offsetting $80 million tariffs.

**【Q&A Highlights】**
- **Bayer Agreement Details**: $120 million net royalty benefit in 2026, $1 billion+ earnings upside from licensing. Cotton licensing begins in U.S., corn licensing accelerates 5 years.
- **Gene Editing Progress**: EU regulatory framework expected Q2, enabling gene-edited products. U.S. disease-resistant corn hybrid to launch within 1-2 years post-approval.
- **Market Share & Demand**: Seed order books strong, North America soy/corn shift manageable. Crop Protection volumes up mid-single digits, biologicals double-digit growth.
- **Free Cash Flow**: 2025 at 45% of EBITDA, 2026 ~40% due to working capital normalization. Separation costs (~$100 million) and Bayer payment impact near-term but strategic.
- **Tariffs & Risks**: $80 million tariff headwind in 2026, primarily China-US trade. Brazil CP pricing stable, but generics pressure persists.


Corteva, Inc. (CTVA) Q4 2025 Earnings Call Transcript

- **Strategic Separation**: Split into Seed and Crop Protection businesses to accelerate innovation and unlock $80-100M in dis-synergies.
- **Record Performance**: Q3 EBITDA up 19%, full-year guidance raised to $3.8-3.9B with 14% growth.
- **New Product Momentum**: Varpelgo insecticide and biologicals driving $9B Crop Protection pipeline, with Spinosyns near $900M in 2025.
- **Free Cash Flow Strength**: $1.9B free cash flow on track, supporting $1B buybacks and 50% conversion rate.
- **2026 Growth Drivers**: Double-digit Seed growth, Crop Protection biologicals expansion, and $4.1B EBITDA target.

**【CEO Summary Section】**
- Announced intent to split into two public companies (Seed and Crop Protection) by mid-2026 to unlock growth potential.
- Seed business delivered $200M in productivity benefits and expects double-digit trade penetration for Conkesta in Brazil next year.
- Crop Protection introduced new insecticide Varpelgo (expected $750M peak revenue) and achieved 19% EBITDA growth year-to-date.
- Raised full-year 2025 EBITDA guidance to $3.8-3.9B (14% growth) and operating EPS to $3.25-3.35.
- Free cash flow conversion rate maintained at ~50% with $1B share buybacks on track.

**【CFO Financial Commentary】**
- Organic sales up 11% Q3/2025, driven by Seed and Crop Protection volume gains.
- Operating EBITDA margin expanded 320bps to 25.3%, with $500M+ cost savings from deflation and productivity.
- Year-to-date Seed royalty expense reduced by $90M, nearing royalty neutrality.
- Full-year free cash flow guidance reaffirmed at $1.9B, supported by strong EBITDA and lower capex.

**【Q&A Highlights】**
- **Crop Protection Pipeline**: $9B pipeline with Varpelgo and biologicals driving high single-digit growth in 2026.
- **Biologicals Growth**: Spinosyns revenue near $900M, with double-digit growth in new products (Rinskor, Arylex).
- **Latin America Risk Management**: Barter system covers 40% of Brazil sales, limiting credit risk exposure.
- **Seed Market Share**: Gained share in North America corn and soy, with Conkesta Brazil penetration set to double in 2026.
- **2026 Outlook**: Full-year EBITDA $4.1B (mid-single-digit growth), with Crop Protection pricing stabilizing globally.

Corteva, Inc. (CTVA) Q3 2025 Earnings Call Transcript

- **Record First Half Performance**: Operating EBITDA up 14% to $3.35B, margin +300 bps. Seed EBITDA +250M, CP EBITDA +150M.
- **Cost Savings Acceleration**: $450M net cost improvement target for 2025 (vs. $400M prior), with $400M+ first-half savings.
- **Guidance Raise**: Full-year EBITDA midpoint +$100M to $3.8B, EPS +21% to $3.10. Free cash flow +$300M to $1.9B.
- **2026 Growth Drivers**: Seed out-licensing ($4B+ Latin America opportunity), CP new products (e.g., Haviza, Reklemel), and 2027 framework on track.
- **Key Risks**: Farmer liquidity, Brazilian Real hedge impacts, CP pricing headwinds.

**【CEO Opening Remarks】**
- **Strong Q2 and H1 Performance**: Revenue grew 7% organically, driven by Seed and Crop Protection (CP) businesses. Operating EBITDA expanded by 300 basis points to nearly 31%, with $400M+ in cost savings from raw material deflation and productivity.
- **Seed Business Excellence**: 280 bps margin expansion, 28% EBITDA growth, and $70M net royalty benefit from out-licensing gains. North America corn acreage up mid-single digits, with Vorceed and PowerCore hybrids driving share gains.
- **Crop Protection Momentum**: 350 bps margin expansion, 8% volume growth (led by Latin America), and double-digit new product/biologicals growth. Brazil volume up due to planted area expansion and direct sales channel growth.
- **2025 Guidance Update**: Full-year operating EBITDA raised to $3.8B (midpoint), +13% YoY. Free cash flow guidance increased to $1.9B, with 50% conversion rate. Dividend increased 6%, and $1B+ share buybacks planned.
- **2026 Outlook**: Constructive on growth, with focus on Seed out-licensing, CP new products, and cost productivity. On track to meet 2027 framework of $1B EBITDA growth through 2027.

**【CFO Financial Commentary】**
- **Q2 Financials**: Organic sales +7%, EBITDA +13%, operating margin +215 bps. Seed price +1%, volume +2%; CP price -2%, volume +8%.
- **H1 Financials**: Organic sales +5%, EBITDA +14%, margin +300 bps. Seed EBITDA +250M, CP EBITDA +150M. $400M+ cost savings from raw material deflation and productivity.
- **Updated Guidance**: Full-year EBITDA $3.75-3.85B (midpoint +13%), EPS $3-3.20 (midpoint +21%). Free cash flow $1.9B, driven by earnings growth and tax benefits.
- **Key Risks**: Farmer liquidity (prepaid deposits), Brazilian Real hedge impacts, and CP pricing headwinds.

**【Q&A Highlights】**
- **Back-Half Expectations**: Seed volume growth in Brazil and Argentina, CP volume growth in new products/biologicals. Seed pricing low single digits, CP pricing low-mid single-digit declines. $450M net cost improvement target for 2025.
- **Free Cash Flow**: $1.9B guidance reflects $900M+ first-half cash flow and lower interest expense. Conversion rate 50% due to earnings growth and tax savings.
- **Seed Acreage**: Brazil summer crop orders 90% booked, safrinha orders 40% booked (unusually early). Argentina area recovery underway.
- **CP Pricing Dynamics**: Brazil generics stable but competitive. China exports stable, production tightening. 2026 CP pricing outlook improving.
- **Tariffs and Inventory**: Supply chain resilient through multi-sourcing. Inventories expected flat to prior year by end-2025.


Corteva, Inc. (CTVA) Q2 2025 Earnings Call Transcript

- **Q1 EBITDA Surges 15% YoY**, driven by $200M cost savings and Biologicals/CP new product growth.
- **$400M Net Cost Savings Target** on track, supporting $3.7B EBITDA guidance.
- **US Corn Acres +5%**, Enlist soybean tech adoption hits 65% of US soy acres.
- **Brazil Soy Out-licensing** surpasses 3M units, with corn ethanol growth creating structural value.
- **Hybrid Wheat Innovation** poised for $1B annual revenue by 2027.

**【CEO Opening Remarks】**
- Q1 2025 EBITDA increased 15% YoY, with 390bps margin expansion driven by cost savings and growth in Biologicals, new CP products, and seed out-licensing.
- Full year guidance reaffirmed at $3.7B operating EBITDA, with $400M net cost savings target on track.
- US corn acres projected +5%, Enlist soybean tech planted on 65% of US soy acres, and Brazil soybean out-licensing surpasses 3M units.

**【CFO Financial Highlights】**
- Organic sales +3% YoY (Seed +2%, Crop Protection +3%), with Seed pricing +3% and CP volume +5%.
- Operating EBITDA $1.2B (up 15% YoY), margin 27% (up 390bps), driven by $200M cost savings and lower input costs.
- Full year guidance includes $50M tariff impact, manageable within $3.7B EBITDA range.

**【Q&A Key Takeaways】**
- **Tariffs**: $50M direct impact, mitigation efforts underway; no impact on full year guidance.
- **Brazil Corn Expansion**: Ethanol demand to drive 30% of Brazil ethanol from corn by 2026, solidifying Corteva's leadership.
- **New Products**: Biologicals and CP new products deliver double-digit volume growth, offsetting low single-digit price declines.
- **Wheat Innovation**: Hybrid wheat tech could generate $1B annual revenue, with 2027 launch on track.
- **Asia-Pacific Growth**: Expanding germplasm penetration in APAC, targeting smallholder farmers with next-gen technologies.

Corteva (CTVA)-8 May 25-2025 Q1 Earnings call transcript

- **2024 Strong Finish**: EBITDA flat at $3.4B with 20% margin, despite headwinds. Crop Protection Q4 volume +16%, Brazil safrinha corn driving growth.
- **2025 Growth Drivers**: 10% EBITDA target ($3.7B midpoint), fueled by Seed tech adoption (+300 new hybrids) and Crop Protection biologicals (+20%+ growth).
- **Cost Efficiency**: $500M+ savings in 2024, $400M+ 2025 self-help actions (royalty, deflation, productivity). Share buybacks to continue at $1B+ annually.
- **FX Mitigation**: Brazil-focused strategies (pricing, new products) offset $275M EBITDA FX headwinds, with 100+ bps margin expansion planned.


**【CEO Summary Section】**
- **2024 Performance**: Organic sales grew 1%, with EBITDA stable at $3.4 billion and a 20% margin. Crop Protection saw double-digit volume growth in Q4, driven by Brazil demand.
- **2025 Outlook**: Targeting 10% EBITDA growth to $3.7 billion (midpoint), with Seed and Crop Protection led by new products (spinosyns, biologicals) and cost savings ($400M+).
- **Strategic Initiatives**: $1B+ in R&D investment, 100+ basis points margin expansion annually, and $1B share buybacks in 2025.

**【CFO Financial Commentary】**
- **2024 Results**: GAAP net income $420M, non-GAAP EPS $1.08. Free cash flow $1.7B, up 50% YoY, with $1.5B returned to shareholders via dividends and buybacks.
- **2025 Guidance**: EBITDA $3.6-3.8B, +10% at midpoint. FX headwinds ($275M) offset by price/mix gains, new product growth (biologicals +20%), and $50M+ royalty savings.
- **Cost Management**: 2024 delivered $500M in gross cost savings; 2025 targets $400M+ from deflation, productivity, and footprint optimization.

**【Q&A Key Themes】**
- **Market Dynamics**: Crop Protection stabilizing with balanced channel inventories; Seed demand driven by yield tech (Enlist E3 soybeans at 65% market share).
- **FX Risks**: Brazilian real and Canadian dollar headwinds ($125M+ EBITDA impact), but pricing actions and new products mitigate downside.
- **Execution Focus**: Seed COGS improvement in Brazil, Crop Protection new product ramp (spinosyns +20% Q4), and $1B+ EBITDA growth by 2027 via out-licensing and innovation.


Actual				0.59	1.26	-0.39	0.04	0.79	1.4	-0.14	0.08	0.97	1.64	-0.12	0.16	1.16	1.6	-0.23	0.15	0.89	1.83	-0.49	0.32	1.13	2.2	-0.23	0.22
Forecast				0.399	1.2403	-0.4218	-0.049	0.6485	1.2659	-0.313	0.0843	0.815	1.4552	-0.2207	0.0519	0.9374	1.5843	-0.2404	0.0587	0.8229	1.7208	-0.303	0.3123	0.8743	1.886	-0.5067	0.2229
Surprise	0.00%	0.00%	0.00%	+47.87%	+1.59%	+7.54%	+181.63%	+21.82%	+10.59%	+55.27%	-5.10%	+19.02%	+12.70%	+45.63%	+208.29%	+23.75%	+0.99%	+4.33%	+155.54%	+8.15%	+6.35%	-61.72%	+2.47%	+29.25%	+16.65%	+54.61%	-1.30%

CTVA

CTVA fundamentals

CTVA Q4 2025 Earnings

Earnings Call

You can ask Aime

CTVA

CTVA fundamentals

CTVA Q4 2025 Earnings

Earnings Call

CTVA Earnings Call Summary for Q4/20259:00 AM on Feb 4, 2026

CTVA Earnings Call Summary for Q3/20259:00 AM on Nov 5, 2025

CTVA Earnings Call Summary for Q2/20259:00 AM on Aug 7, 2025

CTVA Earnings Call Summary for Q1/20259:00 AM on May 8, 2025

CTVA Earnings Call Summary for Q4/20249:00 AM on Feb 6, 2025

You can ask Aime